Serial CTRS was developed from routine-care CTs and externally validated across 10 institutions and the phase 1 GARNET trial, covering ICI monotherapy and combinations across all lines. Multivariable ...

Please provide your email address to receive an email when new articles are posted on . The addition of ribociclib to front-line letrozole prolonged OS among postmenopausal women with hormone receptor ...

Please provide your email address to receive an email when new articles are posted on . Datopotamab deruxtecan improved PFS compared with standard chemotherapy for patients with advanced non-small ...

SAN DIEGO -- The addition of an immune checkpoint inhibitor (ICI) to chemotherapy up front improved overall survival (OS) in patients with advanced or recurrent endometrial cancer, regardless of ...

Final overall survival data from the IMvigor130 trial revealed similar results with atezolizumab alone, chemotherapy alone, and atezolizumab plus chemotherapy in patients with advanced urothelial ...